Fibrous Dysplasia, Polyostotic clinical trials
The registry lists 23 studies for Fibrous Dysplasia, Polyostotic across 7 countries. 5 are recruiting or about to start. 19 of them are mainly about Fibrous Dysplasia, Polyostotic (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Fibrous Dysplasia, Polyostotic studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Institute of Dental and Craniofacial Research (NIDCR) (8) · Hospices Civils de Lyon (5) · AstraZeneca (2) · University Hospital, Clermont-Ferrand (1) · Boston Children's Hospital (1) · Children's Mercy Hospital Kansas City (1) · Yale University (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)
What is being tested here
Drugs under test in Fibrous Dysplasia, Polyostotic studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Denosumab | 1 | 0 | 2 |
| Burosumab | 0 | 0 | 1 |
| Tocilizumab | 0 | 0 | 1 |
| Fulvestrant | 0 | 0 | 1 |
| Letrozole | 0 | 0 | 1 |
| Alendronate | 0 | 0 | 1 |
| Anastrozole | 0 | 0 | 1 |
| Pegvisomant | 0 | 1 | 1 |
Drug classes tested here Aromatase inhibitors 3
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The study
- Jan 2027Fibrous Dysplasia: An Epidemiological and Correlational Evaluation of Multimodal Data · Istituto Ortopedico Rizzoli
Who these studies take
Of the 5 Fibrous Dysplasia, Polyostotic studies recruiting now, 3 (60%) set no upper age limit and 0 (0%) stop at 75 or younger. 3 (60%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (60%) | 3 (60%) |
| 18 | 5 (100%) | 5 (100%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 5 (100%) | 5 (100%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 5 (100%) | 5 (100%) |
| 75 | 5 (100%) | 5 (100%) |
| 85 | 5 (100%) | 5 (100%) |
Across all 23 studies, recruiting or not: 26% stop at 75 or younger and 26% at 65; 74% take children; 17% are for women only and 0% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 23 of 23. search them.
- Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright SyndromeRecruitingNCT000017271 country
- Fibrous Dysplasia: An Epidemiological and Correlational Evaluation of Multimodal DataRecruitingNCT075697311 country
- Fibrous Dysplasia, McCune-Albright Syndrome Patient RegistryRecruitingNCT032316441 country
- DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)RecruitingNCT05966064Phase 41 country
- Hepato-pancreato-biliary Abnormalities in Fibrous Dysplasia of Bone/McCune Albright SyndromeRecruitingNCT061773271 country
- Pain in Fibrous DysplasiaCompletedNCT04125862Not applicable1 country
- PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot StudyCompletedNCT07476768Not applicable1 country
- Assessment of Femoral Failure Load and Fracture Risk in Rare Bone Disorders Using MEKANOS Tool. Case Study of Fibrous Dysplasia of Bone/McCune Albright SyndromeActive, not recruitingNCT075079421 country
- Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous DysplasiaCompletedNCT05509595Phase 21 country
- Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous DysplasiaCompletedNCT05419050Phase 21 country
- TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONECompletedNCT01791842Phase 21 country
- Faslodex in McCune-Albright SyndromeCompletedNCT00278915Phase 26 countries
- Determination of Circulating Autotaxin in Patients With GNAS or PTH AbnormalitiesCompletedNCT046717191 country
- Effectiveness of Medical Management of Fibrous Dysplasia of Bone.CompletedNCT054228331 country
- Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright SyndromeWithdrawnNCT035201531 country
- Histamine Responsiveness in McCune-Albright SyndromeCompletedNCT003180971 country
- Effects of Letrozole on Precocious Puberty Due to McCune Albright SyndromeCompletedNCT00006174Phase 11 country
- Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright SyndromeCompletedNCT000019731 country
- Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeCompletedNCT00001728Phase 21 country
- Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright SyndromeCompletedNCT000018511 country
- Arimidex in McCune Albright SyndromeCompletedNCT00055302Phase 24 countries
- A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright SyndromeCompletedNCT00017927Phase 31 country
- Testolactone for the Treatment of Girls With LHRH Resistant Precocious PubertyCompletedNCT00001181Phase 21 country